Previous close | 16.48 |
Open | 16.33 |
Bid | 17.08 x 800 |
Ask | 17.16 x 300 |
Day's range | 16.20 - 17.46 |
52-week range | 9.67 - 17.85 |
Volume | |
Avg. volume | 1,019,955 |
Market cap | 1.494B |
Beta (5Y monthly) | -1.48 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.37 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 36.63 |
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51% Day One receives rare pediatric disease priority review voucher Conference call and webcast to be April 24, 8:30 a.m. Eastern Time BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceuti
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]